## Hidenaga Yamamori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8186460/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	12.6	450
2	Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neuroscience Letters, 2013, 556, 37-41.	2.1	88
3	Glutamate Networks Implicate Cognitive Impairments in Schizophrenia: Genome-Wide Association Studies of 52 Cognitive Phenotypes. Schizophrenia Bulletin, 2015, 41, 909-918.	4.3	65
4	Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes. Nature Communications, 2020, 11, 859.	12.8	59
5	Estimated cognitive decline in patients with schizophrenia: A multicenter study. Psychiatry and Clinical Neurosciences, 2017, 71, 294-300.	1.8	51
6	Effect of Clozapine on DNA Methylation in Peripheral Leukocytes from Patients with Treatment-Resistant Schizophrenia. International Journal of Molecular Sciences, 2017, 18, 632.	4.1	49
7	Genetic Overlap between General Cognitive Function and Schizophrenia: A Review of Cognitive GWASs. International Journal of Molecular Sciences, 2018, 19, 3822.	4.1	49
8	Brain morphological and functional features in cognitive subgroups of schizophrenia. Psychiatry and Clinical Neurosciences, 2020, 74, 191-203.	1.8	46
9	Genome-Wide Association Study of Cognitive Decline in Schizophrenia. American Journal of Psychiatry, 2013, 170, 683-684.	7.2	42
10	Performance on the <scp>W</scp> echsler <scp>A</scp> dult <scp>I</scp> ntelligence <scp>S</scp> caleâ€ <scp>III</scp> in <scp>J</scp> apanese patients with schizophrenia. Psychiatry and Clinical Neurosciences, 2014, 68, 534-541.	1.8	38
11	Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the â€Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. Psychiatry and Clinical Neurosciences, 2019, 73, 642-648.	1.8	35
12	Prescription patterns in patients with schizophrenia in Japan: Firstâ€quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)―project. Neuropsychopharmacology Reports, 2020, 40, 281-286.	2.3	32
13	Association between the superior longitudinal fasciculus and perceptual organization and working memory: A diffusion tensor imaging study. Neuroscience Letters, 2020, 738, 135349.	2.1	28
14	Differentiation of schizophrenia using structural MRI with consideration of scanner differences: A realâ€world multisite study. Psychiatry and Clinical Neurosciences, 2020, 74, 56-63.	1.8	27
15	Eye movement abnormalities and their association with cognitive impairments in schizophrenia. Schizophrenia Research, 2019, 209, 255-262.	2.0	23
16	Unmet needs of patients with major depressive disorder – Findings from the â€~ <scp>E</scp> ffectiveness of <scp>G</scp> uidelines for <scp>D</scp> issemination and <scp>E</scp> ducation in <scp>P</scp> sychiatric <scp>T</scp> reatment ( <scp>EGUIDE</scp> )' project: A nationwide dissemination, education, and evaluation study. Psychiatry and Clinical Neurosciences, 2020, 74, 667-669	1.8	20
17	Polygenetic components for schizophrenia, bipolar disorder and rheumatoid arthritis predict risk of schizophrenia. Schizophrenia Research, 2016, 175, 226-229.	2.0	17
18	Ethnicity-Dependent Effects of Schizophrenia Risk Variants of the <i>OLIG2</i> Gene on <i>OLIG2</i> Transcription and White Matter Integrity. Schizophrenia Bulletin, 2020, 46, 1619-1628.	4.3	17

HIDENAGA YAMAMORI

#	Article	IF	CITATIONS
19	Polygenic Architecture of Human Neuroanatomical Diversity. Cerebral Cortex, 2020, 30, 2307-2320.	2.9	16
20	Eye Movement Abnormalities in Major Depressive Disorder. Frontiers in Psychiatry, 2021, 12, 673443.	2.6	16
21	Plasma levels of matrix metalloproteinaseâ€9 (MMPâ€9) are associated with cognitive performance in patients with schizophrenia. Neuropsychopharmacology Reports, 2020, 40, 150-156.	2.3	15
22	Abnormalities of eye movement are associated with work hours in schizophrenia. Schizophrenia Research, 2018, 202, 420-422.	2.0	14
23	Predicting work outcome in patients with schizophrenia: Influence of IQ decline. Schizophrenia Research, 2018, 201, 172-179.	2.0	13
24	Eyeâ€movement characteristics of schizophrenia and their association with cortical thickness. Psychiatry and Clinical Neurosciences, 2019, 73, 508-509.	1.8	13
25	Behavioral characterization of mice overexpressing human dysbindin-1. Molecular Brain, 2014, 7, 74.	2.6	12
26	Longer telomeres in elderly schizophrenia are associated with long-term hospitalization in the Japanese population. Journal of Psychiatric Research, 2018, 103, 161-166.	3.1	12
27	Genome-wide Association Analysis of Eye Movement Dysfunction in Schizophrenia. Scientific Reports, 2018, 8, 12347.	3.3	10
28	Platelet-derived growth factor BB: A potential diagnostic blood biomarker for differentiating bipolar disorder from major depressive disorder. Journal of Psychiatric Research, 2021, 134, 48-56.	3.1	10
29	Amyloid-β down-regulates XIAP expression in human SH-SY5Y neuroblastoma cells. NeuroReport, 2004, 15, 851-854.	1.2	9
30	Impaired inhibition of return during free-viewing behaviour in patients with schizophrenia. Scientific Reports, 2021, 11, 3237.	3.3	9
31	Comparison of eye movements in schizophrenia and autism spectrum disorder. Neuropsychopharmacology Reports, 2020, 40, 92-95.	2.3	8
32	Effects of age and sex on eye movement characteristics. Neuropsychopharmacology Reports, 2021, 41, 152-158.	2.3	8
33	Multiple alterations in glutamatergic transmission and dopamine D2 receptor splicing in induced pluripotent stem cell-derived neurons from patients with familial schizophrenia. Translational Psychiatry, 2021, 11, 548.	4.8	6
34	Serum levels of glial cell line-derived neurotrophic factor as a biomarker for mood disorders and lithium response. Psychiatry Research, 2021, 301, 113967.	3.3	5
35	Positive association between insight and attitudes toward medication in Japanese patients with schizophrenia: Evaluation with the Schedule for Assessment of Insight ( <scp>SAI</scp> ) and the Drug Attitude Inventory – 10 Questionnaire ( <scp>DAI</scp> â€10). Psychiatry and Clinical Neurosciences, 2021, 75.187-188	1.8	4
36	Methylation Analysis in Monozygotic Twins With Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine. Frontiers in Psychiatry, 2021, 12, 734606.	2.6	4

HIDENAGA YAMAMORI

#	Article	IF	CITATIONS
37	Neurocognitive features, personality traits, and social function in patients with schizophrenia with a history of violence. Journal of Psychiatric Research, 2022, 147, 50-58.	3.1	4
38	Relationship between autistic traits and social functioning in healthy individuals. Neuropsychopharmacology Reports, 2022, 42, 226-229.	2.3	3
39	Relationship between white matter microstructure and work hours. Neuroscience Letters, 2021, 740, 135428.	2.1	2
40	The de novo Q1042R POGZ mutation in sporadic ASD disrupts the neuronal differentiation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-67.	0.0	0